The effectiveness of topical cream containing pimecrolimus 1% in preventing scar formation: an in-vivo study.

Aim Hypertrophic scars occur due to overactivity of fibroblasts, leading to increased collagen deposition and the formation of new blood vessels. Existing therapies have limitations, underscoring the need for alternative options. Pimecrolimus, a calcineurin inhibitor, exhibits immunomodulatory effec...

Descripción completa

Detalles Bibliográficos
Publicado en:Wound Practice & Research Vol. 34; no. 2; pp. 1 - 8
Autores principales: </strong>, <strong>Author(s), Lashkarizadeh, Farzaneh, Khoshnazar, Seyedeh Mahdieh, Karimzadeh, Amin
Formato: Journal Article
Publicado: Cambridge Publishing Jun2026
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=195130156&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 195130156
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        18376304
        639G
      jtl: Wound Practice & Research
      issn: 18376304
      maglogo: N
    pubinfo:
      dt: Jun2026
      vid: 34
      iid: 2
      pid: 66266
      pub: Cambridge Publishing
    artinfo:
      ui:
        195130156
        10.33235/wpr.34.2.69-75
        195130156
      ppf: 1
      ppct: 7
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: The effectiveness of topical cream containing pimecrolimus 1% in preventing scar formation: an in-vivo study.
      aug:
        au:
          </strong>, <strong>Author(s)
          Lashkarizadeh, Farzaneh
          Khoshnazar, Seyedeh Mahdieh
          Karimzadeh, Amin
        affil: Mohammadreza Lashkarizadeh 1, Mahdiyeh Lashkarizadeh 4, Department of General Surgery, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran
      sug:
      ab: Aim Hypertrophic scars occur due to overactivity of fibroblasts, leading to increased collagen deposition and the formation of new blood vessels. Existing therapies have limitations, underscoring the need for alternative options. Pimecrolimus, a calcineurin inhibitor, exhibits immunomodulatory effects; however, its influence on hypertrophic scars remains unclear. Methods This study explored the impact of pimecrolimus on scar development in vivo. We used 10 female New Zealand rabbits. Round full-thickness dermal wounds were created on each ear. Pimecrolimus 1% cream was applied to the wounds on the left ear, while the right ear received a placebo (Vaseline), applied daily for six weeks. Scar diameter (mm) was measured weekly using calipers. At the conclusion of the study, histopathological assessment was conducted to evaluate fibroblast density, vascularisation and collagen deposition. Results Scar diameter decreased progressively in both groups, with a significantly greater reduction observed in the Pimecrolimus-treated group by week 6 (p<0.05). Histological analysis also indicated significant reductions in fibroblast density (p<0.01), vascularisation (p<0.001), and collagen deposition (p<0.05) in the pimecrolimus group relative to controls. Conclusion Pimecrolimus reduced hypertrophic scar formation, presumably by influencing fibroblast proliferation, angiogenesis and collagen remodeling. Further trials are necessary to validate its therapeutic potential as a non-invasive treatment for hypertrophic scars.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N